ANNOVIS BIO INC. COMMON STOCK

Annovis to Host Year-End Investor Webcast on December 11, 2024

25 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

12 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Annovis Bio Reports Third Quarter Financial Results and Provides Business Update

11 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

07 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024

22 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs

15 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

03 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

02 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra

30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

05 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Reports Second Quarter Financial Results and Provides Business Update

15 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

06 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

24 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

16 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team

09 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap

02 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap

27 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

26 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data

25 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024

18 Jun 2024 08:00:00 By Nasdaq GlobeNewswire